NeogenFRA:NG2 +5.08%68 Quick Ratio is 2.84 as of Feb. 2026, which is 56% below its 10-year median of 6.46. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €10.73 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Neogen ranks better than 65.77% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Neogen's quick ratio for the quarter that ended in Feb. 2026 was 2.84.
Neogen has a quick ratio of 2.84. It generally indicates good short-term financial strength.
The historical rank and industry rank for Neogen's Quick Ratio or its related term are showing as below:
FRA:NG2'
s Quick Ratio Range Over the Past 10 Years
Min: 2.22 Med: 6.46 Max: 10.9
Current: 2.84
During the past 13 years, Neogen's highest Quick Ratio was 10.90. The lowest was 2.22. And the median was 6.46.
FRA:NG2's Quick Ratio is ranked better than 65.77% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 1.89
vs FRA:NG2: 2.84
Neogen (FRA:NG2) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Neogen Quick Ratio Related Terms
Neogen Quick Ratio Historical Data
* Premium members only.
The historical data trend for Neogen's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NG2 vs UFPT, ALMR, BFLY: Quick Ratio Comparison
For the Medical Devices subindustry, Neogen's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Neogen's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Neogen's Quick Ratio for the fiscal year that ended in May. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (FRA:NG2) has a Quick Ratio of 2.84 as of Feb. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Neogen and its competitors. This is 56% below median its historical median of 6.46. Over the past decade, Neogen's Quick Ratio has ranged from 2.22 to 10.90. According to the industry distribution chart, Neogen ranks #292 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 34.2%.
Is Neogen's Quick Ratio too high?
Neogen's current Quick Ratio of 2.84 is 56% below median its 10-year median of 6.46. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 10.90. The Medical Devices & Instruments industry median Quick Ratio is 1.89. Neogen's value of 2.84 is 50.3% above this industry median. Based on the distribution chart, Neogen ranks #292 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Quick Ratio compare to UFPT and ALMR?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #292 out of 853 companies for Quick Ratio. This puts Neogen in the upper half of its industry. The industry median Quick Ratio is 1.89. Neogen's value of 2.84 is 50.3% above this benchmark. Historically, Neogen's own Quick Ratio has ranged from 2.22 to 10.90 over the past decade. While the company's 10-year median is 6.46 vs. the industry median of 1.89, Neogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neogen's current Quick Ratio of 2.84 is 50.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Neogen and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neogen's current Quick Ratio is 2.84, which is 56% below median its own 10-year median of 6.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.73, compared to a current price of €8.40 — trading 21.8% below its estimated fair value. The current Quick Ratio is 2.84, which is 56% below median its 10-year median of 6.46 and 50.3% above the Medical Devices & Instruments industry median of 1.89. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Quick Ratio is 2.84 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be undervalued.
The current stock price of €8.40 is trading 21.8% below its estimated GF Value™ of €10.73.
GuruFocus considers Neogen to be Modestly Undervalued.
Key valuation signals for FRA:NG2:
Quick Ratio: 2.84 (56% below median its 10-year median of 6.46)
GF Value™: €10.73 vs. price of €8.40 (21.8% below fair value)
Industry Position: 50.3% above the Medical Devices & Instruments median (#292 of 853)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score
Get the complete analysis for FRA:NG2
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
